Catalyst Founder and CEO, Nancy Myers, moderated a panel on Thursday, September 24th, 2020 at the (virtual) ASGCT Policy Summit. The panel was on “Overcoming Regulatory Challenges in Gene Therapy Development.”
The panelists and their presentation topics are:
- Anne-Virginie Eggimann, Senior Vice-President, Regulatory Science, bluebird bio
“Regulatory considerations to improve gene therapy development throughout life cycle” - Ying Huang, Ph.D., Pharmacologist, Pharmacology/Toxicology Branch, FDA
“Selecting appropriate animal models for clinical success” - Becky Schweighardt, Ph.D., Senior Director, Immunogenicity Assessment, BioMarin
“Addressing immunogenicity in clinical trials”
For more information and to register, click HERE.